XNAS · Biotechnology
Last stored close · Nov 10, 2026
Close · Nov 10, 2026
$136.64-1.60%
Model Target
—
not published for this name
Implied upside
—
vs the model target
Valuation methods
—
no method met the standard
TickerWhale Score
62/100
Positive
Score components
TickerWhale View
Kymera Therapeutics scores 62 out of 100 overall, which we rate positive. Technical is its strongest area and Valuation its weakest.
What helps
- Technical
- Quality & growth
- Risk
What to watch
- Valuation
Quality & growth
30%55Moderate
- Revenue growth 134.8%
- EPS growth n/a
Valuation
25%37Weak
- P/E -44.8
- EV/Sales 126.6
Price history
Intraday to five-year windows are free with an account
Members switch between 1D, 1M, 6M, 1Y, 2Y and 5Y and see the live price. Signed out, this is the one-year stored series the technicals below are computed from.
Market intelligence
Peer position
#40 / 139sector rank by TickerWhale Score
TickerWhale Score 62 vs sector average 54.6 (+7.4)
Revenue growth (industry)Top 16%
Return on equity (industry)Top 50%
Technical analysis
our read · what classic indicators sayTickerWhale technical read
96/100Strong vs universe
Ranks 96th of 100 covered names on our technical composite — the composite itself scores 84/100 · 25% of the TickerWhale Score
Classic chart indicators
Buy
5 buy · 2 sell · 1 neutral of 8 votes
TickerWhale rates KYMR's technical setup strong — 96th percentile of the covered universe. Classic chart indicators lean buy, pointing the same way.
Moving averages
9 / 9constructive
- vs 200-day+38.6%
- vs 50-day+17.4%
Momentum
Mixed
- RSI (14)67 · neutral
- Stochasticsell
- CCIbuy
- Williams %Rsell
Trend
Constructive
- ADX (14) trend strength41· trending
- MACD (12,26,9)buy(histogram 2.046)
How the classic verdict is reached
Moving averages (9) agree on buy — 9 buy vs 0 sell — and carry one vote between them.
Oscillators (7) vote individually: 4 buy · 2 sell · 1 neutral.
Result — 5 buy vs 2 sell of 8 votes = Buy. Neutral votes never decide the verdict.
Fundamentals & valuation
2026-11-10 · revised_latestValuation multiples
- P/E (TTM)-44.8 · TTM loss
- P/S (TTM)127.8
- P/B8.9
- EV/EBITDA—
- EV/Sales126.6
- PEG—
Profitability & returns
- Gross margin—
- Net margin-285.3%
- ROE-19.7%
- Debt/Equity0.00
Growth
- Revenue growth (YoY)134.8%
- EPS growth (YoY)—
Green favourable · red stretched — multiples and D/E vs industry peers, margins and growth vs absolute thresholds.
Market capitalisation — $13.4B
Fundamentals history
Reported statement totals across recent periods.
Fundamentals are stored revised/latest (ADR-009): each period reflects the most recent vendor refresh, NOT point-in-time as-reported values. Do not use this series to claim what was known on a past date.
Model Target
Model Target — Under Review
Our valuation methods do not currently agree closely enough for us to publish a single target for this company. We would rather say so than print a number we cannot stand behind. The TickerWhale Score still reflects quality, growth and momentum.
Peers
| Company | Score | Pulse | P/E | P/E fwd | P/B | EV/Sales | Price | Chg | Estimate | Upside | Rev. gr. |
|---|---|---|---|---|---|---|---|---|---|---|---|
| KYMRCurrentKymera Therapeutics | 62 | 84 | -44.8 | — | 8.9 | 126.6 | $136.64 | -1.60% | +134.8% | ||
| EXELExelixis | 82 | 88 | 21.3 | — | 9.9 | 7.4 | $70.58 | -1.62% | +9.2% | ||
| KNSAKiniksa Pharmaceuticals International plc. - | 79 | 81 | 98.2 | — | 12.1 | 9.3 | $95.02 | -3.79% | +58.9% | ||
| THCTenet Healthcare | 79 | 81 | 10.9 | — | 5.2 | 1.6 | $290.27 | +0.44% | +7.5% | ||
| INCYIncyte | 76 | 67 | 15.5 | — | 3.9 | 3.6 | $120.30 | -1.30% | +26.9% | ||
| LIVNLivaNova | 76 | 84 | 27.2 | — | 3.9 | 3.3 | $91.14 | -1.59% | +12.4% |
News, sentiment, the Street view and Ask Willy are free with an account
A free account shows the stories attached to this name, the Sentiment Signal breakdown, analyst consensus, the options read and the AI narration of the model output.